2019年美国血液学会免疫性血小板减少症指南的2022年审查
美国血液学会(ASH)工作组对2019年ASH免疫性血小板减少症(ITP)指南进行审查,检索2017年5月至2022年7月的系统综述和临床试验,共识别193项研究,经摘要和全文审查后,ASH质量委员会认可针对成人ITP二线管理进行聚焦更新,并将继续年度监测以评估是否需要进一步修订。
要点
- ASH工作组审查2019年ITP指南,检索2017年5月至2022年7月的系统综述和临床试验。
- 共识别193项研究,102项经摘要审查,54项经全文审查。
- ASH质量委员会认可针对成人ITP二线管理进行聚焦更新,并将继续年度监测。
核心结论
- 基于审查,ASH质量委员会认可针对成人ITP二线管理进行聚焦更新,并将继续年度监测和全面审查2019年ASH ITP指南以评估额外修订时机。
研究设计与样本
- ASH要求专家工作组对2019年ASH ITP指南进行审查,以决定是否需要及何时修订指南。
- 更新检索Medline和Embase,使用与2019年ASH指南相同的检索词,限系统综述和临床试验,时间2017年5月至2022年7月。
主要发现
- 共识别193项研究,102项进行摘要审查,54项进行全文审查。
- 每项研究基于与先前推荐在人群、优先结局、新结局和研究设计方面的相关性进行评估。
- 审查者评估数据是否改变现有推荐强度或方向,或值得制定新推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2019 American Society of Hematology (ASH) guidelines for immune thrombocytopenia (ITP) included recommendations on the management of adults (recommendations 1-9) and children (recommendations 10-21) with primary ITP . We describe here the results of a review of the 2019 guidelines by a working group of experts requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated Medline and Embase search applied the same search terms as in the 2019 ASH guidelines, limited to systematic reviews and clinical trials, from May 2017 to July 2022. There were 193 studies identified, 102 underwent abstract reviews, and 54 full reviews. Each study was assessed based on relevance to the previous recommendation with regard to the population, prioritized outcomes, new outcomes, and study design. Reviewers assessed if the data would change the strength or the directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the ASH Committee on Quality endorsed a focused update on second-line management for adults with ITP. In addition, there will be continued annual monitoring and reviewing of the 2019 ASH guidelines on ITP in full to evaluate when there is sufficient new evidence to warrant additional revisions.
引用
- Neunert CE, Arnold DM, Grace RF, et al. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Adv. 2024. PMID: 38608258. doi:10.1182/bloodadvances.2023012541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。